Scientific Imperative of Clinical Trial Diversity and Impact on Covid-19

Genetic variation (eg ancestral background) may play a key role in how a patient responds to a drug or medical products, yet clinical trials often lack diversity and minority-equity. Having minority populations represented in clinical evaluation ensures robustness and enhances predictability of how new treatments might perform on these demographics. Join Alekhya Pochiraju as she explores how non-Caucasian and underserved populations must be appropriately represented in clinical trials to ensure the efficacy of treatments for all populations.

Alekhya is a Biomarker Operations Manager at Genentech where she provides clinical oncology biomarker operations expertise. She believes, with the future of healthcare geared towards personalized medicine, biomarkers are a critical element of cancer drug development and cancer therapeutics. Her recent talk at Girl Geek’s Elevate and conference at Biomarkers & Precision Medicine USA Congress and Salesforce Women’s Summit, focus on health equity disparity among minorities and people of color, specifically on the disproportionate impact COVID-19 pandemic can have. Alekhya holds an undergraduate degree from BMS College of Engineering, India in Biotechnology Engineering and a masters degree from Northeastern University in Biotechnology. Prior to joining Genentech, Alekhya worked in quality technology at Fluidigm and Sanofi-Genzyme.


Starts: October 22, 2020 12:00 pm EDT

Ends: October 22, 2020 1:00 pm EDT

Venue: Webinar